Sign in
Taking people in South KoreaPhase 3

Compares two radiotherapy schedules with temozolomide in older adults with glioblastoma

Compares standard and shorter radiation with temozolomide in adults 70 and older with glioblastoma.

Key facts

Who runs it
Severance Hospital
Where
Seoul, South KoreaSee the site
Trial code
Registry title
Conventional Versus Hypofractionated Radiotherapy With Temozolomide in Elderly Glioblastoma
Status
Recruiting
Phase
Phase 3
People taking part
178 people, planned
Started
1 Feb 2025
Expected to end
31 Dec 2030
Type of study
Interventional, 2 groups
Treatments tested
  • Hypofractionated radiotherapy
  • Conventional radiotherapy
  • Temozolomide
Record updated
21 May 2025

Who can take part

AI summary

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for people aged 70 or older with newly diagnosed glioblastoma. It compares two radiotherapy schedules, both given together with temozolomide.

Age
70 years or older
Sex
All sexes can join.
Disease stage
Newly diagnosed glioblastoma (2021 World Health Organization classification), with no more than 4 weeks between the pathological diagnosis and randomization.
Earlier treatment
No earlier brain radiotherapy and no earlier systemic chemotherapy. Steroid dose must be stable or decreasing, if steroids are needed.
Biomarker or test result
The O6-methylguanine-DNA-methyltransferase promoter methylation status must be known.

Main reasons for not taking part

  • Spinal leptomeningeal carcinomatosis
  • Another cancer in the past, with a few exceptions
  • Serious active infection or other serious medical conditions
  • Known allergy to temozolomide or similar compounds
  • Taking part in another clinical trial

The registry criteria, word for word

Show all 20 criteriaShow less

Who can take part

  • newly diagnosed glioblastoma according to the 2021 World Health Organization classification
  • interval of ≤4 weeks between pathological diagnosis and randomization
  • aged 70 years or older
  • gadolinium-enhanced MRI within 72 hours of surgery
  • known o6-methylguanine-DNA-methyltransferase promoter methylation status
  • Karnofsky performance score ≥60
  • stable or decreasing dose of steroid (if necessary)
  • no history of brain radiotherapy
  • no history of any systemic chemotherapy
  • adequate hematological, renal and hepatic functions for temozolomide
  • able to start radiotherapy within 3 weeks from randomization

Who cannot take part

  • history of cancer other than the followings:
  • completely excised non-melanoma skin cancer
  • cancers without any evidence of residual disease for 5 years or longer
  • patients with serious active infection or other serious underlying medical conditions
  • patients with known hypersensitivity to temozolomide or compounds with similar chemical composition to temozolomide
  • patients with spinal leptomeningeal carcinomatosis
  • carcinoma in situ of the cervix
  • patients with psychological issues that cannot comply to the protocol
  • patients who are currently participating in other clinical trials

Where in South Korea

  • Severance hospitalSeoul, South KoreaContact: Chan Woo Wee, MD, PhDTaking people

About the trial

What the trial wants to find out

In newly diagnosed glioblastoma patients aged 70 years or older who are suitable for concurrent temozolomide, the optimal dose of radiation therapy is controversial . The purpose of this study is to compare conventional radiotherapy of 60 Gy (6 weeks) versus hypofractionated radiotherapy of 40 Gy (3 weeks) in terms of overall survival as the primary endpoint along with progression-free survival, toxicity, quality of life, and prognostic biomarkers.

The 2 groups in the trial

  • Hypofractionated radiochemotherapyTreatment being tested

    Radiotherapy: 40.05 Gy in 15 fractions (daily treatment, 5 per week) Temozolomide: concurrent (75 mg/m2/day qd) and adjuvant (6 cycles)

    Treatment: Hypofractionated radiotherapy and Temozolomide

  • Conventional radiochemotherapyTreatment being tested

    Radiotherapy: 60 Gy in 30 fractions (daily treatment, 5 per week) Temozolomide: concurrent (75 mg/m2/day qd) and adjuvant (6 cycles)

    Treatment: Conventional radiotherapy and Temozolomide

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
Randomized Phase III Study of Conventional Versus Hypofractionated Radiotherapy Combined With Temozolomide in Elderly Glioblastoma Patients
Plain-language title
Compares two radiotherapy schedules with temozolomide in older adults with glioblastomaGenerated from the registry record. The registry title is the official one.
AI summary
From the trial's eligibility criteria. Read by machine on 12 November 2026.
Record updated
21 May 2025